GSK pill works in uncomplicated gonorrhea
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: biotechnology
The FDA isn’t afraid to yank a disappointing drug
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Liver disease MASH is next target for obesity drugs in development
As drugmakers race to join the obesity drug market ignited by the approval of Wegovy…
STAT+: Ocular Therapeutix moves in the right direction, and Alnylam tries to calm some nerves
This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes…
What do CEOs owe the world?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Annovis Bio delivers candor on its Parkinson’s study, even if it doesn’t inspire much confidence
Annovis Bio had my biotech bull%^&! meter running red after it made a late change…
.jpg)
Humira’s legacy, CEO symbolism, and genomic surgery
What do CEOs owe the world? Did Humira break the system? And can you CRISPR…
STAT+: San Diego biotech Neurocrine Biosciences joins PhRMA
WASHINGTON — Neurocrine Biosciences, a biotech company based in California, has joined the drug lobbying…
Novavax’s money is going in the wrong direction
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Actually Wegovy is good for dialysis companies, dialysis provider says
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Ring Therapeutics, a gene therapy startup, lays off 20% of staff
Ring Therapeutics, a gene therapy startup launched by Flagship Pioneering, has laid off just under…
STAT+: AbbVie CEO Gonzalez to step down after a decade fiercely defending its top seller, Humira
AbbVie announced Tuesday that CEO Richard Gonzalez, who has managed the company’s ascent since it…
Bayer, short on cash, reaches into shareholders’ pockets
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
STAT+: In ‘major milestone,’ FDA approves first cell therapy for solid tumors
Nearly four decades after its first conception, the first TIL therapy, an immunotherapy that harvests…
STAT+: Flagship Pioneering startup lays off a third of staff
Sonata Therapeutics, a startup created two years ago through the merger of two Flagship Pioneering…
Alnylam thickened the plot
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: For unlucky mountaineers, tundra explorers and the unhoused, a new drug could avert the ravages of frostbite
Two days after his right hand froze, Hart Bezner realized for the first time that…
Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking
Has PhRMA lost its fangs? Are 11th-hour changes ominous for clinical trials? And what’s next…
Pharma’s contractors might finally be on the rebound
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Gaming Amylyx stock reactions to the next ALS drug test, and a chat with CRISPR’s CEO about a new investor
This week, a preview of the TUDCA study in ALS and thoughts on how it…
STAT+: The Jewish American and Palestinian American scientists who’ve been partnering for 14 years on science’s toughest challenges
WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads…
Replicate’s srRNA rabies vaccine effective in Phase 1
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Biotech launches with $135 million for Vertex-competing pain medicine
After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched…
STAT+: Biogen Alzheimer’s drug launch off to slow start
Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about…
The need to know biotech news stories today
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Startup BioAge raises $170 million Series D for Zepbound combination therapy
A California biotech developing a combination therapy with the obesity drug Zepbound has raised a…
STAT+: KalVista pill reduces swelling symptoms caused by genetic disease, achieving goal of late-stage study
KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced…
STAT+: Judge tosses PhRMA lawsuit over Medicare power to negotiate drug prices
WASHINGTON — A federal district judge on Monday granted the Biden administration’s request to dismiss…
STAT+: Gilead to acquire CymaBay for $4.3 billion, adding new treatment for liver disease
Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new…
Psychedelic investment continues to ramp up
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Does Moderna’s RSV vaccine lose efficacy faster than others?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
AI in medicine, detangling hype, and Icelandic DNA
Has AI really solved biology? What can machines teach us about medicine? And what’s a…
STAT+: A looming cancer vaccine test for Gritstone Bio, and pushback about Novartis-MorphoSys
This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview…
STAT+: A looming cancer vaccine test for Gristone Bio, and pushback on my Novartis-MorphoSys take
This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview…
Gilead sours on the ‘don’t eat me’ business
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: A gene therapy designed to heal skin wounds helped preserve a boy’s vision
In the clinical trial, the gene therapy seemed to be helping the boy’s skin wounds…
The GLP-1 panic is alive and well
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: RayzeBio co-founder, industry veterans launch new biotech VC with $310 million
Three biotech VC veterans, including one of the co-founders of radiopharma success story RayzeBio, are…
STAT+: Why Eli Lilly’s earnings didn’t quite live up to the hype
Eventually, the luckiest companies get to deal with a very particular problem: what to do…
STAT+: Why Novartis is going to walk away from its acquisition of MorphoSys
Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The…
Vertex still knows how to do what it does best
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Eli Lilly reports tirzepatide MASH success during Q4 earnings
The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve…
STAT+: Novartis to buy German biotech MorphoSys for $2.9 billion
Novartis said late Monday it has agreed to buy German biotech MorphoSys and its pipeline…
STAT+: Diabetes treatments have improperly listed patents that should be removed, analysis finds
More than half of the injector-pen patents for several widely used diabetes treatments — including…
STAT+: Novo’s Catalent deal is great for GLP-1s. But what about drug manufacturing?
Sixteen billion dollars is a lot of money. But Monday’s announcement that the parent company…
Regeneron is interested in obesity treatments that combat muscle loss
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: ARCH Venture Partners is raising $3 billion for a life sciences fund
ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3…
STAT+: The lessons of Aduhelm, Biogen’s Alzheimer’s drug that was not to be
Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy,…
What makes a drug a blockbuster — or a cautionary tale?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Listen: Vertex’s polarizing data, Aduhelm’s adieu, & an FDA icon
What makes a blockbuster? Can biotech learn from Aduhelm? And how do you replace a…